WO2002055547A2 - Sfrp and peptide motifs that interact with sfrp and methods of their use - Google Patents

Sfrp and peptide motifs that interact with sfrp and methods of their use Download PDF

Info

Publication number
WO2002055547A2
WO2002055547A2 PCT/US2002/000869 US0200869W WO02055547A2 WO 2002055547 A2 WO2002055547 A2 WO 2002055547A2 US 0200869 W US0200869 W US 0200869W WO 02055547 A2 WO02055547 A2 WO 02055547A2
Authority
WO
WIPO (PCT)
Prior art keywords
sfrp
peptide
seq
ala
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/000869
Other languages
English (en)
French (fr)
Other versions
WO2002055547A9 (en
WO2002055547A3 (en
Inventor
Jeffrey S. Rubin
Aykut Uren
Nicole Joy Horwood
Matthew Todd Gillespie
Brian K. Kay
Bernard Weisblum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Vincents Institute of Medical Research
US Department of Health and Human Services
Original Assignee
St Vincents Institute of Medical Research
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP02707454A priority Critical patent/EP1387854B1/en
Priority to US10/466,136 priority patent/US7488710B2/en
Priority to ES02707454T priority patent/ES2385666T3/es
Priority to JP2002556615A priority patent/JP4029041B2/ja
Priority to AU2002241859A priority patent/AU2002241859B2/en
Priority to AT02707454T priority patent/ATE550345T1/de
Priority to CA2434672A priority patent/CA2434672C/en
Priority to DK02707454.1T priority patent/DK1387854T3/da
Application filed by St Vincents Institute of Medical Research, US Department of Health and Human Services filed Critical St Vincents Institute of Medical Research
Publication of WO2002055547A2 publication Critical patent/WO2002055547A2/en
Publication of WO2002055547A9 publication Critical patent/WO2002055547A9/en
Anticipated expiration legal-status Critical
Publication of WO2002055547A3 publication Critical patent/WO2002055547A3/en
Priority to US12/019,567 priority patent/US8334260B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0643—Osteoclasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
PCT/US2002/000869 2001-01-10 2002-01-10 Sfrp and peptide motifs that interact with sfrp and methods of their use Ceased WO2002055547A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2434672A CA2434672C (en) 2001-01-10 2002-01-10 Sfrp and peptide motifs that interact with sfrp and methods of their use
ES02707454T ES2385666T3 (es) 2001-01-10 2002-01-10 SFRP y motivos peptídicos que interactúan con SFRP y sus métodos de uso
JP2002556615A JP4029041B2 (ja) 2001-01-10 2002-01-10 ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
AU2002241859A AU2002241859B2 (en) 2001-01-10 2002-01-10 sFRP and peptide motifs that interact with sFRP and methods of their use
AT02707454T ATE550345T1 (de) 2001-01-10 2002-01-10 Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
EP02707454A EP1387854B1 (en) 2001-01-10 2002-01-10 Sfrp and peptide motifs that interact with sfrp and methods of their use
US10/466,136 US7488710B2 (en) 2001-01-10 2002-01-10 SFRP and peptide motifs that interact with SFRP and methods of their use
DK02707454.1T DK1387854T3 (da) 2001-01-10 2002-01-10 SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf
US12/019,567 US8334260B2 (en) 2001-01-10 2008-01-24 sFRP and peptide motifs that interact with sFRP and methods of their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26090801P 2001-01-10 2001-01-10
US60/260,908 2001-01-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10466136 A-371-Of-International 2002-01-10
US12/019,567 Division US8334260B2 (en) 2001-01-10 2008-01-24 sFRP and peptide motifs that interact with sFRP and methods of their use

Publications (3)

Publication Number Publication Date
WO2002055547A2 true WO2002055547A2 (en) 2002-07-18
WO2002055547A9 WO2002055547A9 (en) 2002-10-31
WO2002055547A3 WO2002055547A3 (en) 2003-11-20

Family

ID=22991151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000869 Ceased WO2002055547A2 (en) 2001-01-10 2002-01-10 Sfrp and peptide motifs that interact with sfrp and methods of their use

Country Status (11)

Country Link
US (2) US7488710B2 (enExample)
EP (1) EP1387854B1 (enExample)
JP (3) JP4029041B2 (enExample)
AT (1) ATE550345T1 (enExample)
AU (1) AU2002241859B2 (enExample)
CA (1) CA2434672C (enExample)
CY (1) CY1112875T1 (enExample)
DK (1) DK1387854T3 (enExample)
ES (1) ES2385666T3 (enExample)
PT (1) PT1387854E (enExample)
WO (1) WO2002055547A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061029A1 (en) * 2006-11-10 2008-05-22 Wyeth Aryl sulfonamide derivatives and methods of their use
US7795386B2 (en) 2004-12-23 2010-09-14 Molmed Spa Peptides comprising an isoDGR motif
US8053194B2 (en) 2004-03-31 2011-11-08 Kazuo Shinya Labeling substance and chimeric substance and method for preparing the same and method for capturing, structurally analyzing and/or identifying biological substance by means of the labeling substance
EP3696192A1 (en) * 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010010266A (es) * 2008-03-21 2010-12-14 Adlyfe Inc Uso de pireno para llevar peptidos a traves de la barrera hematoencefalica.
NZ589539A (en) * 2008-05-16 2012-08-31 Bioexx Specialty Proteins Ltd Oilseed protein concentrates and isolates, and processes for the production thereof
JP2013006783A (ja) * 2011-06-22 2013-01-10 Nagasaki Univ 荷重感知遺伝子
FI3116521T3 (fi) * 2014-03-14 2024-10-30 Univ New York State Res Found Luun kasvun ja luun rappeutumisen neurogeeninen regulaatio
DK3139979T3 (da) 2014-05-07 2023-10-09 Boehringer Ingelheim Int Enhed, forstøver og fremgangsmåde
US12344886B2 (en) * 2017-06-15 2025-07-01 Technion Research & Development Foundation Limited Compositions and methods for detection of genomic variations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5726156A (en) 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5861483A (en) 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238839A (en) 1988-02-09 1993-08-24 Dana Farber Cancer Institute Nucleic Acids Encoding proteins which induce immunological effector cell activation and chemattraction, vectors, and recombinant cells
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
CA2117282A1 (en) 1991-11-22 1993-05-27 Ofer Lider Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprosing them
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
WO1997039357A1 (en) 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Wnt RECEPTOR COMPOSITIONS AND METHODS
US5851984A (en) 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
PT932678E (pt) 1996-09-24 2006-07-31 Tanox Inc Familia de genes que codificam peptidos relacionados com apoptose, peptidos por eles codificados e metodos para sua utilizacao
US5939271A (en) 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
BR9808545A (pt) 1997-04-16 2000-05-23 Amgen Inc ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
US6043053A (en) 1997-05-23 2000-03-28 Smithkline Beecham Corporation Wnt-3 polynucleotides
AU7704498A (en) 1997-05-29 1998-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human frp and fragments thereof including methods for using them
EP1012262A4 (en) 1997-08-12 2002-11-06 Human Genome Sciences Inc HFLP PROTEIN HFLP
WO1999026960A2 (en) 1997-11-25 1999-06-03 Millennium Pharmaceuticals, Inc. Genes encoding frizzled-like proteins
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11196864A (ja) 1998-01-08 1999-07-27 Deinabekku Kenkyusho:Kk 破骨細胞の分化を誘導する方法
US6110718A (en) * 1998-03-20 2000-08-29 Wayne State University Mammalian putative phosphatidylinositol-4-phosphate-5-kinase
WO2001057188A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
AU7131200A (en) 1999-09-13 2001-04-17 Wyeth Pharmaceutical compositions and methods of using secreted frizzled related protein
US6600018B1 (en) * 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
JP2002181893A (ja) * 2000-12-11 2002-06-26 Mitsubishi Electric Corp 半導体装置の検査方法および検査装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5726156A (en) 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5861483A (en) 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
B.R. WONG ET AL., J. EXP. MED., vol. 186, 1997, pages 2075 - 2080
D. WALLACH ET AL., ANNU. REV. IMMUNOL., vol. 17, 1999, pages 331 - 367
D.M. ANDERSON ET AL., NATURE, vol. 390, 1997, pages 175 - 179
MESHUL ET AL., J. NEUROCHEM., vol. 67, 1996, pages 1965
S.J. BAKER; E.P. REDDY, ONCOGENE, vol. 17, 1998, pages 3261 - 3270
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR
UREN ET AL., J. BIOL. CHEM, vol. 275, 2000, pages 4374 - 4382
UREN ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 4374 - 4382

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8053194B2 (en) 2004-03-31 2011-11-08 Kazuo Shinya Labeling substance and chimeric substance and method for preparing the same and method for capturing, structurally analyzing and/or identifying biological substance by means of the labeling substance
JP4832291B2 (ja) * 2004-03-31 2011-12-07 一男 新家 ラベル用物質とキメラ物質、これらの物質の作製方法、並びに該ラベル用物質を用いて生体物質を捕捉、構造解析又は／及び同定する方法
US7795386B2 (en) 2004-12-23 2010-09-14 Molmed Spa Peptides comprising an isoDGR motif
WO2008061029A1 (en) * 2006-11-10 2008-05-22 Wyeth Aryl sulfonamide derivatives and methods of their use
EP3696192A1 (en) * 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
WO2020165453A1 (en) * 2019-02-15 2020-08-20 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease

Also Published As

Publication number Publication date
US7488710B2 (en) 2009-02-10
CY1112875T1 (el) 2016-04-13
US20040077828A1 (en) 2004-04-22
US8334260B2 (en) 2012-12-18
ES2385666T3 (es) 2012-07-30
JP4029041B2 (ja) 2008-01-09
CA2434672C (en) 2014-03-25
JP4248583B2 (ja) 2009-04-02
PT1387854E (pt) 2012-06-26
JP2009005704A (ja) 2009-01-15
JP2007300920A (ja) 2007-11-22
JP2005501508A (ja) 2005-01-20
WO2002055547A9 (en) 2002-10-31
JP4248600B2 (ja) 2009-04-02
WO2002055547A3 (en) 2003-11-20
AU2002241859B2 (en) 2007-07-19
DK1387854T3 (da) 2012-07-09
EP1387854A2 (en) 2004-02-11
EP1387854B1 (en) 2012-03-21
US20080145884A1 (en) 2008-06-19
ATE550345T1 (de) 2012-04-15
CA2434672A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
US8334260B2 (en) sFRP and peptide motifs that interact with sFRP and methods of their use
US7541183B2 (en) Growth and differentiation of adult muscle stem cells with activators or inhibitors of Wnt signaling
EP2401293B1 (en) Designer ligands of tgf-beta superfamily
JP2022044589A (ja) ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用
JP4530129B2 (ja) スーパー抗原
US20150209407A1 (en) Methods for the treatment and prevention of osteoporosis and bone-related diseases
AU2002241859A1 (en) sFRP and peptide motifs that interact with sFRP and methods of their use
JP2016512958A (ja) 上皮幹細胞の液体培養
US20040248803A1 (en) Compositions of active Wnt protein
WO2009043908A2 (en) Novel marker genes for regulatory t cells from human blood
US8735355B2 (en) Methods of use of fragments of secreted frizzled related protein, sFRP
US6846908B2 (en) DCR-5 bone affecting ligand
WO1996000240A1 (en) Novel protein and process for producing the same
JP4989850B2 (ja) ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
WO2004035627A1 (en) Modulation of tgfbeta-like signalling pathways
WO1998037195A9 (en) Morphogenic proteins
WO1998037195A1 (en) Morphogenic proteins
KR20190005240A (ko) Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드를 포함하는 골 및 연골 질환 치료용 조성물 및 그의 이용
MURAMATSU Search for New Cell-Surface Recognition Molecules Important in Mammalian Embryogenesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

Free format text: PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 2002241859

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2434672

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10466136

Country of ref document: US

Ref document number: 2002556615

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002707454

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002707454

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002241859

Country of ref document: AU